Poor agreement was identified regarding MRI- and classification-defined axial spondyloarthritis (axSpA) and inflammatory back pain diagnoses in patients with psoriatic disease.
Diagnosis of axial spondyloarthritis (axSpA) and inflammatory back pain among patients with psoriatic disease may vary between whole spine MRI and classification-defined criteria, according to study findings published in RMD Open: Rheumatic & Musculoskeletal Diseases.
Despite high prevalence of axial disease among patients with psoriatic arthritis (PsA), no accepted definition for the condition exists, in which treatment recommendations are based from those of ankylosing spondylitis (AS).
Moreover, researchers note that studies comparing axial PsA with AS have found notable differences in the former, including lower prevalence and intensity of inflammatory back pain (IBP), spinal mobility restriction and radiographic sacroiliitis, and more frequent asymmetric spine and sacroiliac joints (SIJ) involvement.
“While imaging evidence of sacroiliitis or spondylitis is desirable for identifying patients with axial involvement, radiographic diagnosis has low inter-reliability and intra-reliability,” they added. “MRI has become an essential tool for axSpA diagnosis and MRI sacroiliitis is included in the classification criteria for axSpA. Only a few small studies have investigated axial findings by MRI among patients with PsA.”
Deriving whole spine and SIJ MRI data, the study authors examined inflammatory and structural lesions consistent with SpA in patients with PsA and in those with psoriasis with clinical suspicion of axPsA (N = 93; 69.9% PsA), and their correlation with clinical features and axSpA classification criteria.
In the cross-sectional retrospective analysis, MRI spondylitis and/or sacroiliitis (MRI-SpA) was defined according to Assessment of Spondyloarthritis International Society (ASAS) consensus and by radiologist impression. Considering MRI as the gold standard, agreement between MRI-SpA and different IBP definitions (Berlin/ASAS/rheumatologist criteria) and the axSpA classification criteria were calculated.
Of the study cohort, the majority of patients experienced back pain (81.7%), in which 57% of patients were found to have IBP by the rheumatologist impression and 36.6% according to both ASAS and Berlin criteria.
Comparably, overall prevalence of MRI findings consistent with SpA was low, with MRI-SpA found in 9.7% of patients by ASAS definition and in 12.9% by radiologist impression, of which 25% had isolated spondylitis. Low agreement was identified between the 3 IBP definitions and MRI-SpA.
“IBP definition by rheumatologist had a higher sensitivity for MRI-SpA by ASAS and radiologist (50%-55.6%) but with low specificity (42%-42.9%), while Berlin and ASAS IBP criteria had higher specificity for MRI-SpA by ASAS and radiologist (61.9%-63%) but with low sensitivity (22.2%-33.3%),” they noted.
Furthermore, late onset of back pain or asymptomatic patients were identified to account for most cases with MRI-SpA not meeting axSpA or IBP criteria. Findings of the univariate and multivariable regression analyses additionally identified male sex as being the only variable to be associated with radiologist-MRI-SpA (OR, 6.91; 95%CI, 1.42-33.59).
“Clinical and epidemiological differences between axPsA and other axSpA may explain these findings,” concluded researchers. “Current efforts to study axial involvement in PsA led by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and ASAS should help to define this entity in patients with PsA.”
Reference
Diaz P, Feld J, Eshed I, Eder L. Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings. RMD Open. 2022;8:e002011. doi:10.1136/ rmdopen-2021-002011
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More